Novel disease-specific promoters for use in gene therapy for Parkinson's disease.
Research output: Contribution to journal › Article
Gene therapy is a promising therapeutic tool for Parkinson's disease (PD), but there is a lack of evaluated cell specific promoters that are relevant for the disease. We have chosen PD relevant promoter candidates for gene therapy vectors based on either previous studies; Drd1a, Drd2 and pDyn, or from a microarray study on parkinsonian patients; ACE, DNAJC3, GALNS, MAP1a and RNF25. These candidates have been evaluated in rat striatum to determine their suitability for use in cell specific vectors. The promoters had a neuronal specificity of 91-100%. The efficiency of the promoters was variable, but RNF25, DNAJC3 and MAP1a were comparable to widely used ubiquitous promoters. MAP1a was also affected by dopamine depletion.
|Research areas and keywords||
Subject classification (UKÄ) – MANDATORY
|Publication status||Published - 2012|
Related research output
Erika Elgstrand, 2013, Department of Experimental Medical Science, Lund Univeristy. 116 p.
Research output: Thesis › Doctoral Thesis (compilation)